# Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Source: https://onco.cc/trials/nct02659514/  
OnCo record `nct02659514` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, completed.

## Summary

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer is a phase 2 interventional study registered as NCT02659514 by Spectrum Pharmaceuticals, Inc, with 67 participants recorded, started 2016-02-22 and reaching its primary completion in 2020-03-11. Interventions recorded: Poziotinib. Conditions recorded: Breast Cancer.

Linked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02659514
- Phase: 2
- Setting: A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
- Sponsor: Spectrum Pharmaceuticals, Inc
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT02659514: https://clinicaltrials.gov/study/NCT02659514

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Poziotinib](https://onco.cc/drugs/poziotinib/)
- companies: [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct02659514.json